|
Gene: MYO1E |
Gene summary for MYO1E |
Gene summary. |
Gene information | Species | Human | Gene symbol | MYO1E | Gene ID | 4643 |
Gene name | myosin IE | |
Gene Alias | FSGS6 | |
Cytomap | 15q22.2 | |
Gene Type | protein-coding | GO ID | GO:0001568 | UniProtAcc | Q12965 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4643 | MYO1E | CCI_1 | Human | Cervix | CC | 1.62e-21 | 1.91e+00 | 0.528 |
4643 | MYO1E | CCI_2 | Human | Cervix | CC | 7.39e-23 | 1.88e+00 | 0.5249 |
4643 | MYO1E | CCI_3 | Human | Cervix | CC | 3.58e-19 | 1.26e+00 | 0.516 |
4643 | MYO1E | CCII_1 | Human | Cervix | CC | 1.41e-08 | 5.29e-01 | 0.3249 |
4643 | MYO1E | H2 | Human | Cervix | HSIL_HPV | 2.61e-02 | 2.01e-01 | 0.0632 |
4643 | MYO1E | HTA11_3410_2000001011 | Human | Colorectum | AD | 8.76e-16 | -5.77e-01 | 0.0155 |
4643 | MYO1E | HTA11_2951_2000001011 | Human | Colorectum | AD | 3.70e-08 | -7.12e-01 | 0.0216 |
4643 | MYO1E | HTA11_347_2000001011 | Human | Colorectum | AD | 6.71e-07 | 5.50e-01 | -0.1954 |
4643 | MYO1E | HTA11_411_2000001011 | Human | Colorectum | SER | 3.42e-07 | 7.17e-01 | -0.2602 |
4643 | MYO1E | HTA11_7862_2000001011 | Human | Colorectum | AD | 6.53e-05 | -4.46e-01 | -0.0179 |
4643 | MYO1E | HTA11_866_3004761011 | Human | Colorectum | AD | 3.15e-04 | -4.01e-01 | 0.096 |
4643 | MYO1E | HTA11_9408_2000001011 | Human | Colorectum | AD | 1.77e-02 | -6.39e-01 | 0.0451 |
4643 | MYO1E | HTA11_8622_2000001021 | Human | Colorectum | SER | 5.74e-07 | -4.93e-01 | 0.0528 |
4643 | MYO1E | HTA11_6801_2000001011 | Human | Colorectum | SER | 2.60e-02 | -6.64e-01 | 0.0171 |
4643 | MYO1E | HTA11_7696_3000711011 | Human | Colorectum | AD | 8.34e-05 | -3.03e-01 | 0.0674 |
4643 | MYO1E | HTA11_7469_2000001011 | Human | Colorectum | AD | 1.35e-03 | -7.60e-01 | -0.0124 |
4643 | MYO1E | HTA11_6818_2000001021 | Human | Colorectum | AD | 1.03e-03 | -4.61e-01 | 0.0588 |
4643 | MYO1E | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.25e-56 | -8.48e-01 | 0.294 |
4643 | MYO1E | HTA11_99999971662_82457 | Human | Colorectum | MSS | 6.78e-24 | -6.64e-01 | 0.3859 |
4643 | MYO1E | HTA11_99999974143_84620 | Human | Colorectum | MSS | 4.25e-44 | -7.42e-01 | 0.3005 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000701510 | Cervix | CC | actin filament organization | 109/2311 | 442/18723 | 4.92e-13 | 2.45e-10 | 109 |
GO:00516567 | Cervix | CC | establishment of organelle localization | 76/2311 | 390/18723 | 3.17e-05 | 5.21e-04 | 76 |
GO:00017018 | Cervix | CC | in utero embryonic development | 71/2311 | 367/18723 | 7.21e-05 | 1.00e-03 | 71 |
GO:00015704 | Cervix | CC | vasculogenesis | 22/2311 | 80/18723 | 1.97e-04 | 2.26e-03 | 22 |
GO:000206410 | Cervix | CC | epithelial cell development | 45/2311 | 220/18723 | 4.14e-04 | 4.21e-03 | 45 |
GO:00300487 | Cervix | CC | actin filament-based movement | 29/2311 | 127/18723 | 6.91e-04 | 6.33e-03 | 29 |
GO:00307057 | Cervix | CC | cytoskeleton-dependent intracellular transport | 40/2311 | 195/18723 | 7.92e-04 | 6.99e-03 | 40 |
GO:00097915 | Cervix | CC | post-embryonic development | 20/2311 | 80/18723 | 1.40e-03 | 1.10e-02 | 20 |
GO:00995157 | Cervix | CC | actin filament-based transport | 8/2311 | 21/18723 | 2.44e-03 | 1.71e-02 | 8 |
GO:00300507 | Cervix | CC | vesicle transport along actin filament | 7/2311 | 19/18723 | 5.65e-03 | 3.25e-02 | 7 |
GO:00480084 | Cervix | CC | platelet-derived growth factor receptor signaling pathway | 14/2311 | 56/18723 | 6.93e-03 | 3.74e-02 | 14 |
GO:0030198 | Cervix | CC | extracellular matrix organization | 52/2311 | 301/18723 | 7.43e-03 | 3.98e-02 | 52 |
GO:0043062 | Cervix | CC | extracellular structure organization | 52/2311 | 302/18723 | 7.92e-03 | 4.17e-02 | 52 |
GO:0045229 | Cervix | CC | external encapsulating structure organization | 52/2311 | 304/18723 | 9.00e-03 | 4.57e-02 | 52 |
GO:000701515 | Cervix | HSIL_HPV | actin filament organization | 43/737 | 442/18723 | 4.77e-08 | 3.59e-06 | 43 |
GO:00030943 | Cervix | HSIL_HPV | glomerular filtration | 6/737 | 25/18723 | 3.40e-04 | 5.39e-03 | 6 |
GO:00972054 | Cervix | HSIL_HPV | renal filtration | 6/737 | 26/18723 | 4.27e-04 | 6.41e-03 | 6 |
GO:003004813 | Cervix | HSIL_HPV | actin filament-based movement | 12/737 | 127/18723 | 4.37e-03 | 3.68e-02 | 12 |
GO:0007015 | Colorectum | AD | actin filament organization | 167/3918 | 442/18723 | 1.65e-16 | 7.94e-14 | 167 |
GO:0002064 | Colorectum | AD | epithelial cell development | 89/3918 | 220/18723 | 2.98e-11 | 3.52e-09 | 89 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0513020 | Cervix | CC | Pathogenic Escherichia coli infection | 63/1267 | 197/8465 | 9.28e-10 | 2.00e-08 | 1.19e-08 | 63 |
hsa05130110 | Cervix | CC | Pathogenic Escherichia coli infection | 63/1267 | 197/8465 | 9.28e-10 | 2.00e-08 | 1.19e-08 | 63 |
hsa0513025 | Cervix | HSIL_HPV | Pathogenic Escherichia coli infection | 28/459 | 197/8465 | 2.36e-06 | 4.61e-05 | 3.73e-05 | 28 |
hsa0513035 | Cervix | HSIL_HPV | Pathogenic Escherichia coli infection | 28/459 | 197/8465 | 2.36e-06 | 4.61e-05 | 3.73e-05 | 28 |
hsa05130 | Colorectum | AD | Pathogenic Escherichia coli infection | 79/2092 | 197/8465 | 1.05e-06 | 1.36e-05 | 8.65e-06 | 79 |
hsa051301 | Colorectum | AD | Pathogenic Escherichia coli infection | 79/2092 | 197/8465 | 1.05e-06 | 1.36e-05 | 8.65e-06 | 79 |
hsa051302 | Colorectum | SER | Pathogenic Escherichia coli infection | 60/1580 | 197/8465 | 3.63e-05 | 4.31e-04 | 3.13e-04 | 60 |
hsa051303 | Colorectum | SER | Pathogenic Escherichia coli infection | 60/1580 | 197/8465 | 3.63e-05 | 4.31e-04 | 3.13e-04 | 60 |
hsa051304 | Colorectum | MSS | Pathogenic Escherichia coli infection | 73/1875 | 197/8465 | 1.10e-06 | 1.48e-05 | 9.06e-06 | 73 |
hsa051305 | Colorectum | MSS | Pathogenic Escherichia coli infection | 73/1875 | 197/8465 | 1.10e-06 | 1.48e-05 | 9.06e-06 | 73 |
hsa051308 | Colorectum | FAP | Pathogenic Escherichia coli infection | 62/1404 | 197/8465 | 1.37e-07 | 3.08e-06 | 1.87e-06 | 62 |
hsa051309 | Colorectum | FAP | Pathogenic Escherichia coli infection | 62/1404 | 197/8465 | 1.37e-07 | 3.08e-06 | 1.87e-06 | 62 |
hsa0513010 | Colorectum | CRC | Pathogenic Escherichia coli infection | 47/1091 | 197/8465 | 1.49e-05 | 3.84e-04 | 2.60e-04 | 47 |
hsa0513011 | Colorectum | CRC | Pathogenic Escherichia coli infection | 47/1091 | 197/8465 | 1.49e-05 | 3.84e-04 | 2.60e-04 | 47 |
hsa0513026 | Endometrium | AEH | Pathogenic Escherichia coli infection | 50/1197 | 197/8465 | 1.72e-05 | 1.86e-04 | 1.36e-04 | 50 |
hsa048144 | Endometrium | AEH | Motor proteins | 42/1197 | 193/8465 | 2.41e-03 | 1.42e-02 | 1.04e-02 | 42 |
hsa05130112 | Endometrium | AEH | Pathogenic Escherichia coli infection | 50/1197 | 197/8465 | 1.72e-05 | 1.86e-04 | 1.36e-04 | 50 |
hsa0481411 | Endometrium | AEH | Motor proteins | 42/1197 | 193/8465 | 2.41e-03 | 1.42e-02 | 1.04e-02 | 42 |
hsa0513027 | Endometrium | EEC | Pathogenic Escherichia coli infection | 51/1237 | 197/8465 | 1.98e-05 | 2.28e-04 | 1.70e-04 | 51 |
hsa048142 | Endometrium | EEC | Motor proteins | 42/1237 | 193/8465 | 4.43e-03 | 2.39e-02 | 1.78e-02 | 42 |
Page: 1 2 3 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MYO1E | SNV | Missense_Mutation | rs778885841 | c.2761N>A | p.Gly921Arg | p.G921R | Q12965 | protein_coding | deleterious(0.02) | probably_damaging(0.96) | TCGA-DM-A1HB-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
MYO1E | SNV | Missense_Mutation | c.2444N>T | p.Lys815Ile | p.K815I | Q12965 | protein_coding | deleterious(0) | probably_damaging(0.926) | TCGA-AG-3727-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
MYO1E | SNV | Missense_Mutation | c.1822N>A | p.Glu608Lys | p.E608K | Q12965 | protein_coding | tolerated(0.36) | possibly_damaging(0.744) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
MYO1E | SNV | Missense_Mutation | rs11539755 | c.1771N>A | p.Glu591Lys | p.E591K | Q12965 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
MYO1E | SNV | Missense_Mutation | rs756487866 | c.1982N>T | p.Ser661Leu | p.S661L | Q12965 | protein_coding | deleterious(0.02) | possibly_damaging(0.496) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
MYO1E | SNV | Missense_Mutation | c.1754N>A | p.Arg585His | p.R585H | Q12965 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
MYO1E | SNV | Missense_Mutation | novel | c.1729N>C | p.Met577Leu | p.M577L | Q12965 | protein_coding | tolerated(0.07) | benign(0.072) | TCGA-A5-A0R9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MYO1E | SNV | Missense_Mutation | rs780053874 | c.506G>A | p.Arg169Gln | p.R169Q | Q12965 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MYO1E | SNV | Missense_Mutation | novel | c.308N>T | p.Arg103Ile | p.R103I | Q12965 | protein_coding | tolerated(0.21) | benign(0.216) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
MYO1E | SNV | Missense_Mutation | c.1623C>A | p.Phe541Leu | p.F541L | Q12965 | protein_coding | tolerated(0.13) | benign(0.439) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |